Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
Source: SeekingAlpha
2026-01-06 14:58:15 ET
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease January 5, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
ProShares UltraPro Short NASDAQ Biotechnology
NASDAQ: ZBIO
ZBIO Trading
-3.91% G/L:
$25.10 Last:
66,235 Volume:
$25.58 Open:
ZBIO Latest News
ZBIO Stock Data
$1,157,322,819
29,738,258
0.79%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
